Good morning,
Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.
So I read something that scared me this morning.
A deep dive from Matthew Baker on LinkedIn, flagging a proposed change buried in the Government's R&D tax reform plan.
What concerned me the most is this…
After 10 years, a company's R&D tax benefit flips from a refundable cash rebate to a non-refundable tax credit.
(Source, LinkedIn)
I did a double-take, and had to confirm for myself…
But there it is, on page 31 of the budget report: “limiting refundability to firms under 10 years of age”.
Translation = if you’re over 10 years old. No tax refund.
(Source, Australian Federal Budget 2026 - Page 31)
Now here's the problem.
It takes, on average, 15 years for a drug to go from preclinical studies through to approval.
(For the few companies fortunate enough to get there.)
And the bulk of the R&D spend lands in the back half of that journey.
The big, expensive, pivotal trials right before FDA approval.
Which, under this proposal, is exactly when the refund disappears. Right when biotechs need it the most.
Right now, I'm typing this from the Stocks in the Vines event.
Six biotech companies are presenting, and there are plenty of interesting stories in the room (some of which I was lucky enough to spend some time with last night).
I just finished breakfast with Chris Burns, the CEO of Amplia (ASX: ATX) and it was great to hear his background starting the company 10 years ago…
Just a science lab and an idea.
A couple of months ago, Amplia delivered a Phase 2 result with 5 complete responses.
Full breakdown here: Amplia (ASX: ATX) Delivers: A Result the Biotech Sector Needed
Now Amplia is gearing up for Phase 3.
The pivotal trial.
The one that matters most.
A 10+ year journey, and this is the next chapter.
The R&D tax incentive was designed to back Australian innovation through the years when it couldn't yet pay for itself.
Year 10, in biotech land, is the pointy end.
The years when R&D reform matters most.
The final chapter before a drug is approved.
Cutting it off at this point is nonsensical.
It's like climbing Everest and pulling the sherpas at the final ridge.
I expect some serious lobbying from the industry to secure a carve-out for biotechs.
Where the journey is measured in decades and not years.
Let’s dive in…
The Pulse Check
Control Bionics (ASX: CBL) appoints the founder of Synchron, Nick Opie, as Non-Executive Director. (CBL)
🪑This is an epic appointment.
Nick co-founded Synchron over 14 years ago, a brain-computer interface technology that was years ahead of Elon Musk’s Neurolink.
Synchron is one of the Australian medtech darlings in private markets and just recently raised US$200 million in a Series D round.
Nick is also my cousin. Good luck!
Argenica Therapeutics (ASX: AGN) establishes a Clinical Advisory Committee of leading stroke and neuroprotection experts to help design its Phase 2b trial. (AGN)
Acrux (ASX: ACR) confirms capital gains from the sale of its shares remain exempt from taxation despite Federal Budget changes to Capital Gains Tax. (ACR)
🪑Nice. I covered this in yesterday’s article: The "Kate Bush" Trade: Acrux's (ASX: ACR) Story
Lumos Diagnostics (ASX: LDX) achieves milestone #7 in the BARDA-funded FebriDx® paediatric clinical study, triggering a US$670K payment. (LDX)
FDA Commissioner Marty Makary resigned Tuesday after a 13-month tenure. Diamantas is named acting commissioner. (The Guardian)
Clarity Pharmaceuticals (ASX: CU6) receives a $9.8M R&D tax refund. (CU6)
See you all tomorrow,
The Armchair Analyst
